Moderna, Inc. $MRNA Shares Newly Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,486 shares of the company’s stock, valued at approximately $864,000.

Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP acquired a new stake in shares of Moderna in the 2nd quarter worth approximately $564,272,000. Wellington Management Group LLP increased its stake in Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after purchasing an additional 103,977 shares in the last quarter. Merck & Co. Inc. purchased a new position in Moderna in the 2nd quarter valued at approximately $161,642,545. Finally, Bamco Inc. NY purchased a new position in Moderna in the 2nd quarter valued at approximately $139,317,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized cancer vaccine intismeran, used with Keytruda, reduced the risk of death or melanoma recurrence by 42% in a late-stage trial. The results bolster the candidate’s potential, though success in additional cancers and eventual commercial impact are not assured. Article: Moderna’s Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
• Neutral Sentiment: Moderna is scheduled to report third-quarter results on Nov. 6. Analysts expect sales of about $888.8 million and a loss of $1.37 per share, making the report a near-term catalyst for investors. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Negative Sentiment: Recent coverage warns that the stock’s steep rally and premium valuation could leave it vulnerable if earnings or vaccine-development news disappoints. One article also flags an obstacle to the cancer vaccine’s success, though the supplied article summary does not specify what it is. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Neutral Sentiment: Prediction markets have begun trading on FDA approval timing for the melanoma vaccine, raising questions about potential information leakage and insider trading. This adds regulatory and market scrutiny but does not itself indicate an FDA decision. Article: What Is Moderna Answering As FDA Vaccine Betting Markets Grow?

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup reaffirmed a “sell” rating on shares of Moderna in a report on Friday, October 23rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research report on Friday, August 28th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Finally, Bank of America lifted their price target on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $107.10.

Moderna Stock Performance

Shares of MRNA opened at $228.44 on Wednesday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $254.48. The company’s 50 day simple moving average is $185.79 and its 200 day simple moving average is $88.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $91.20 billion, a price-to-earnings ratio of -28.59 and a beta of 1.16.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.